Frequently Asked Questions
What is the purpose of the SURF303 trial?
SURF303 is studying dabogratinib, an investigational oral medication, to see if it can safely and effectively treat LG-UTUC.
What makes dabogratinib different from other treatments?
Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for this condition. Other treatments involve upper-tract instillations into the ureter and renal pelvis, while dabogratinib is an oral investigational agent taken as a single, daily dose.
Who can join the trial?
Adults with LG-UTUC may be eligible.
Will I need to stay in the hospital to take part?
No. Dabogratinib is taken at home once a day as a single dose. You will need to visit the study clinic regularly for check-ups and monitoring.
How many people will be in this study?
The study is designed to enroll up to approximately 230 evaluable participants at sites primarily in the United States.
What are the potential benefits?
Dabogratinib is an oral, investigational agent, which means its benefits and risks are still being studied. Participants may benefit if the drug works against their cancer, but there is no guarantee of benefit.
What are the risks?
Like all medicines, dabogratinib may have side effects. The study clinic will explain potential risks and closely monitor participants to ensure safety.
How can I learn more or see if I qualify?
Talk to your doctor about the SURF303 trial or contact a Tyra study representative at tyraclinicaltrials@tyra.bio. You can also visit https://clinicaltrials.gov/study/NCT07265947 for more details.
Talk to your doctor about the SURF303 trial or contact a Tyra study representative at tyraclinicaltrials@tyra.bio. You can also visit clinicaltrials.gov for more details.
